Lina Marcela Zuluaga-Idarraga1, María-Eulalia Tamayo Perez2, Daniel Camilo Aguirre-Acevedo3. 1. Grupo Malaria, Facultad de Medicina. Universidad de Antioquia. Medellín, Colombia. ; Grupo Epidemiología y Bioestadística, Facultad de Medicina. Universidad CES. Medellín, Colombia Medellín. 2. Grupo Académico de Epidemiología Clínica, Facultad de Medicina. Universidad de Antioquia. Medellín, Colombia.; Departamento de Pediatría, Universidad de Antioquia, Fundación Hospital Universitario San Vicente, Medellín, Colombia. 3. Grupo Académico de Epidemiología Clínica, Facultad de Medicina. Universidad de Antioquia. Medellín, Colombia .
Abstract
OBJECTIVE: To compare efficacy and safety of primaquine regimens currently used to prevent relapses by P. vivax. METHODS: A systematic review was carried out to identify clinical trials evaluating efficacy and safety to prevent malaria recurrences by P. vivax of primaquine regimen 0.5 mg/kg/ day for 7 or 14 days compared to standard regimen of 0.25 mg/kg/day for 14 days. Efficacy of primaquine according to cumulative incidence of recurrences after 28 days was determined. The overall relative risk with fixed-effects meta-analysis was estimated. RESULTS: For the regimen 0.5 mg/kg/day/7 days were identified 7 studies, which showed an incidence of recurrence between 0% and 20% with follow-up 60-210 days; only 4 studies comparing with the standard regimen 0.25 mg/kg/day/14 days and no difference in recurrences between both regimens (RR= 0.977, 95% CI= 0.670 to 1.423) were found. 3 clinical trials using regimen 0.5 mg/kg/day/14 days with an incidence of recurrences between 1.8% and 18.0% during 330-365 days were identified; only one study comparing with the standard regimen (RR= 0.846, 95% CI= 0.484 to 1.477). High risk of bias and differences in handling of included studies were found. CONCLUSION: Available evidence is insufficient to determine whether currently PQ regimens used as alternative rather than standard treatment have better efficacy and safety in preventing relapse of P. vivax. Clinical trials are required to guide changes in treatment regimen of malaria vivax.
OBJECTIVE: To compare efficacy and safety of primaquine regimens currently used to prevent relapses by P. vivax. METHODS: A systematic review was carried out to identify clinical trials evaluating efficacy and safety to prevent malaria recurrences by P. vivax of primaquine regimen 0.5 mg/kg/ day for 7 or 14 days compared to standard regimen of 0.25 mg/kg/day for 14 days. Efficacy of primaquine according to cumulative incidence of recurrences after 28 days was determined. The overall relative risk with fixed-effects meta-analysis was estimated. RESULTS: For the regimen 0.5 mg/kg/day/7 days were identified 7 studies, which showed an incidence of recurrence between 0% and 20% with follow-up 60-210 days; only 4 studies comparing with the standard regimen 0.25 mg/kg/day/14 days and no difference in recurrences between both regimens (RR= 0.977, 95% CI= 0.670 to 1.423) were found. 3 clinical trials using regimen 0.5 mg/kg/day/14 days with an incidence of recurrences between 1.8% and 18.0% during 330-365 days were identified; only one study comparing with the standard regimen (RR= 0.846, 95% CI= 0.484 to 1.477). High risk of bias and differences in handling of included studies were found. CONCLUSION: Available evidence is insufficient to determine whether currently PQ regimens used as alternative rather than standard treatment have better efficacy and safety in preventing relapse of P. vivax. Clinical trials are required to guide changes in treatment regimen of malaria vivax.
Authors: Gordon H Guyatt; Andrew D Oxman; Gunn Vist; Regina Kunz; Jan Brozek; Pablo Alonso-Coello; Victor Montori; Elie A Akl; Ben Djulbegovic; Yngve Falck-Ytter; Susan L Norris; John W Williams; David Atkins; Joerg Meerpohl; Holger J Schünemann Journal: J Clin Epidemiol Date: 2011-01-19 Impact factor: 6.437
Authors: David R Hill; J Kevin Baird; Monica E Parise; Linda S Lewis; Edward T Ryan; Alan J Magill Journal: Am J Trop Med Hyg Date: 2006-09 Impact factor: 2.345
Authors: S Looareesuwan; P Wilairatana; R Glanarongran; K A Indravijit; L Supeeranontha; S Chinnapha; T R Scott; J D Chulay Journal: Trans R Soc Trop Med Hyg Date: 1999 Nov-Dec Impact factor: 2.184
Authors: A Y Pinto; A M Ventura; V S Calvosa; M G Silva Filho; M A Santos; R S Silva; J M Souza Journal: J Pediatr (Rio J) Date: 1998 May-Jun Impact factor: 2.197
Authors: Ivor Harris; Wesley W Sharrock; Lisa M Bain; Karen-Ann Gray; Albino Bobogare; Leonard Boaz; Ken Lilley; Darren Krause; Andrew Vallely; Marie-Louise Johnson; Michelle L Gatton; G Dennis Shanks; Qin Cheng Journal: Malar J Date: 2010-09-07 Impact factor: 2.979
Authors: D D Rajgor; N J Gogtay; V S Kadam; M M Kocharekar; M S Parulekar; S S Dalvi; A B Vaidya; N A Kshirsagar Journal: Malar Res Treat Date: 2014-09-10